Prostate Cancer
Advertisement
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic.
The FDA may allow the temporary use of drugs from overseas to alleviate the ongoing cisplatin and carboplatin shortages.
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere.
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel.
Dr. Scott Eggener provides an overview of the advancements in and patient perspectives on Grade Group 1 prostate cancer.
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate.
The SOLAR trial aimed to evaluate the safety and biodistribution of Copper Cu 64 PSMA I&T to detect prostate cancer.
Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors.
Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum.
Foundation Medicine’s comprehensive genomic profiling test identifies mCRPC harboring BRCA1/2-positive mutations.
The phase 3 TITAN study assigned patients with mCSPC apalutamide or placebo with ADT to determine its effects on PFS and OS.
A facility’s case volume of patients with VHR PCa is independently associated with longer OS in this patient group.
The FDA granted approval to AKEEGA given with prednisone for patients with BRCA-positive mCRPC.
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.